Ken Griffin Mannkind Corp Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mannkind Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 133,300 shares of MNKD stock, worth $487,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares

133,300

Previous 64,000 108.28%

Holding current value

$487,878

Previous $321,000 55.14%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$3.71 - $5.04 $539,734 - $733,224	-145,481 Reduced 43.96%	185,494 $693,000
Q1 2025 May 15, 2025	SELL	$4.92 - $6.6 $894,898 - $1.2 Million	-181,890 Reduced 35.47%	330,975 $1.66 Million
Q4 2024 Feb 14, 2025	SELL	$5.93 - $7.44 $3.67 Million - $4.6 Million	-618,518 Reduced 54.67%	512,865 $3.3 Million
Q3 2024 Nov 14, 2024	SELL	$5.01 - $6.7 $2.87 Million - $3.84 Million	-572,608 Reduced 33.6%	1,131,383 $7.11 Million
Q2 2024 Aug 14, 2024	BUY	$4.05 - $5.43 $2.86 Million - $3.83 Million	705,133 Added 70.59%	1,703,991 $8.89 Million
Q1 2024 May 15, 2024	SELL	$3.25 - $5.27 $85,338 - $138,379	-26,258 Reduced 2.56%	998,858 $4.52 Million
Q4 2023 Feb 14, 2024	SELL	$3.34 - $4.29 $2.75 Million - $3.53 Million	-823,142 Reduced 44.54%	1,025,116 $3.73 Million
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.45 $1.75 Million - $2.45 Million	448,829 Added 32.07%	1,848,258 $7.63 Million
Q2 2023 Aug 14, 2023	SELL	$3.72 - $4.79 $5.2 Million - $6.7 Million	-1,397,720 Reduced 49.97%	1,399,429 $5.7 Million
Q1 2023 May 15, 2023	SELL	$3.95 - $5.63 $5.34 Million - $7.61 Million	-1,352,553 Reduced 32.59%	2,797,149 $11.5 Million
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $8.09 Million - $14.4 Million	2,679,299 Added 182.22%	4,149,702 $21.9 Million
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $2.23 Million - $3.25 Million	746,937 Added 103.24%	1,470,403 $4.54 Million
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $1.24 Million - $2.22 Million	-466,272 Reduced 39.19%	723,466 $2.76 Million
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $2.02 Million - $3.44 Million	772,784 Added 185.34%	1,189,738 $4.38 Million
Q4 2021 Feb 14, 2022	SELL	$4.05 - $5.37 $2.56 Million - $3.39 Million	-631,647 Reduced 60.24%	416,954 $1.82 Million
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $1.09 Million - $1.54 Million	280,436 Added 36.51%	1,048,601 $4.56 Million
Q2 2021 Aug 16, 2021	SELL	$3.61 - $5.45 $11.9 Million - $17.9 Million	-3,291,650 Reduced 81.08%	768,165 $4.19 Million
Q1 2021 May 17, 2021	BUY	$3.14 - $6.14 $10.5 Million - $20.6 Million	3,356,590 Added 477.31%	4,059,815 $15.9 Million
Q4 2020 Feb 16, 2021	BUY	$1.79 - $4.04 $123,295 - $278,275	68,880 Added 10.86%	703,225 $2.2 Million
Q3 2020 Nov 16, 2020	BUY	$1.56 - $2.08 $536,601 - $715,468	343,975 Added 118.46%	634,345 $1.19 Million
Q2 2020 Aug 14, 2020	BUY	$0.94 - $2.21 $161,100 - $378,756	171,383 Added 144.04%	290,370 $508,000
Q1 2020 May 15, 2020	BUY	$0.84 - $1.76 $52,400 - $109,790	62,381 Added 110.2%	118,987 $123,000
Q4 2019 Feb 14, 2020	SELL	$1.14 - $1.49 $39,032 - $51,016	-34,239 Reduced 37.69%	56,606 $73,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.44 $15,448 - $21,389	-14,854 Reduced 14.05%	90,845 $113,000
Q2 2019 Aug 14, 2019	BUY	$1.09 - $1.88 $94,535 - $163,052	86,730 Added 457.22%	105,699 $122,000
Q4 2018 Feb 14, 2019	SELL	$1.02 - $2.05 $44,502 - $89,441	-43,630 Reduced 69.7%	18,969 $20,000
Q3 2018 Nov 13, 2018	BUY	$1.01 - $2.19 $45,849 - $99,417	45,396 Added 263.88%	62,599 $0
Q2 2018 Aug 10, 2018	BUY	$1.59 - $2.38 $27,352 - $40,943	17,203 New	17,203 $0

Others Institutions Holding MNKD

# of Institutions

248

Shares Held

161M

Call Options Held

1.24M

Put Options Held

179K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $942M
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account